Studies Show Millions of Americans Driving Under the Influence of Marijuana


Robin Lefferts

January 13th, 2020

App, Exclusive, News, Top News


As many states have legalized marijuana in some form, the safety concerns surrounding cannabis-impaired driving are growing. According to the US Centers for Disease Control and Prevention, recent national estimates of drivers who operate a car under the influence of marijuana are in the millions. CNN discussed these findings in an article, highlighting the fact that about 12 million American adults reported driving under the influence of cannabis, while 2.3 million reported driving under the influence of other illegal drugs. That 12 million number means that 4.7 percent of American adults drive under the influence of marijuana, and 0.9 percent drive under the influence of other drugs.

As a result, marijuana breathalyzer-type devices that could aid police enforcement are in various stages of development. There are significant hurdles, however.

Testing for impairment with alcohol is fairly straightforward, as human bodies process and metabolize alcohol in consistent and definable ways. With cannabis, it’s complicated. THC, the intoxicating ingredient in cannabis, is metabolized by the body into a variety of forms. These metabolites can be found in the body long after the intoxicating effects wear off. Further complicating the picture is that there is no consensus on how much of which kind of THC in the body definitively prove impairment. Lack of scientific knowledge is really the crux of the issue, as the plant’s illegal status has effectively eliminated research for the past 80 years or so.

Research on the way

Fortunately, companies and regulators are recognizing cannabis-impaired driving as a major public safety issue and are actively pursuing solutions. For example, the state of California recently passed legislation to fund research efforts by the California Highway Patrol. The plan is to test drivers in a controlled environment, on CHP property, with the hopes of attaining a clearer picture of what constitutes cannabis impairment.

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) is approaching the problem from the other end, and its research could help inform public policy along the way. The company is developing marijuana breathalyzer devices with the objective of introducing accurate and convenient tools for measuring THC in the breath for both law enforcement and workplace applications.

According to Cannabix, breath is a better indicator of impairment than saliva, blood, or urine because THC only remains in breath for short period of time (2-3 hours) before becoming virtually undetectable, whereas it can remain in other body fluids for many hours, days, or even weeks after smoking. This short time period of detection in breath aligns with the peak impairment window.

Recently, Cannabix was mentioned in a CNN article discussing the obstacles to and potential solutions for the development of a reliable cannabis testing system. The company also recently announced significant improvements in the performance of its FAIMS technology, showing a 6-fold increase in the sensitivity of the THC detection device. Cannabix is developing a more robust device designed for roadside use by law enforcement while simultaneously developing a smaller, more affordable version for home or workplace markets.

Serious Public Safety Issue

A recent survey by AAA indicates that Americans have a fairly casual attitude toward driving while high on cannabis. About 70% of respondents think it’s unlikely that stoned drivers will be caught, which makes sense considering the lack of tools currently available to law enforcement. More concerning is the estimated 14.8 million drivers who reported driving within one hour of cannabis use in the last 30 days. On top of that, 7% of respondents thought it was acceptable to drive after using the drug (compared to 1.6% who approved of drinking and driving).

With the recent rise and spread of cannabis legalization, law enforcement agencies have been tasked with the massive project of educating the public about the dangers of driving high, while simultaneously developing procedures to get impaired drivers off of the streets. At this point, judging by the AAA survey, the education is going slowly and the public has no confidence in the ability of officials to enforce the laws on the books.

Various jurisdictions and organizations are starting to allocate resources to study the thorny question of what constitutes cannabis impaired driving. That type of research could lead to a clearer definition of cannabis impairment. Concurrently, the R&D being conducted by Cannabix Technologies could lead to an accurate and convenient roadside test that can be used to better identify THC in a person’s system during the peak impairment window.

This is a sort of positive feedback loop, created by long-suppressed scientific research made possible by the wave of cannabis legalization sweeping across the continent. Just as scientists are studying the potential medicinal effects of the plant after many years of prohibition, researchers are catching up on the potential downsides of cannabis use in everyday life. No, it’s not Reefer Madness with hallucinations, insanity, and killing. But driving under the influence is a serious public safety concern that is finally being addressed through the proper channels of scientific understanding. It’s about time.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Avatar

About Robin Lefferts



Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading